Jaramillo Segura, S., Krisam, J., Le Cornet, L., Kratzmann, M., Baumann, L., Sauer, T., . . . Schlenk, R. F. (2021). Rationale and design of the 2 by 2 factorial design GnG-trial: A randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. Trials, 22, . https://doi.org/10.1186/s13063-021-05703-w
Chicago-Zitierstil (17. Ausg.)Jaramillo Segura, Sonia, et al. "Rationale and Design of the 2 by 2 Factorial Design GnG-trial: A Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Double-blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AML." Trials 22 (2021). https://doi.org/10.1186/s13063-021-05703-w.
MLA-Zitierstil (9. Ausg.)Jaramillo Segura, Sonia, et al. "Rationale and Design of the 2 by 2 Factorial Design GnG-trial: A Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Double-blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AML." Trials, vol. 22, 2021, https://doi.org/10.1186/s13063-021-05703-w.